Concepts (241)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bivalvia | 9 | 2022 | 20 | 2.010 |
Why?
|
| Hemoglobins | 11 | 2022 | 101 | 1.830 |
Why?
|
| Hermanski-Pudlak Syndrome | 6 | 2019 | 11 | 1.570 |
Why?
|
| Repressor Proteins | 5 | 2021 | 226 | 1.290 |
Why?
|
| Mutation | 10 | 2019 | 1023 | 1.120 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 37 | 0.920 |
Why?
|
| Albinism, Oculocutaneous | 3 | 2013 | 5 | 0.820 |
Why?
|
| Carrier Proteins | 4 | 2018 | 287 | 0.760 |
Why?
|
| Puerto Rico | 16 | 2023 | 1352 | 0.730 |
Why?
|
| Warfarin | 8 | 2016 | 59 | 0.710 |
Why?
|
| Membrane Proteins | 3 | 2014 | 486 | 0.650 |
Why?
|
| Evolution, Molecular | 2 | 2022 | 249 | 0.640 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 7 | 2015 | 49 | 0.620 |
Why?
|
| Histones | 1 | 2018 | 177 | 0.610 |
Why?
|
| Sulfides | 2 | 2022 | 58 | 0.600 |
Why?
|
| Oxygen | 4 | 2022 | 193 | 0.600 |
Why?
|
| RNA, Messenger | 5 | 2018 | 1152 | 0.580 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2016 | 8 | 0.570 |
Why?
|
| Anticoagulants | 8 | 2016 | 97 | 0.550 |
Why?
|
| Focal Dermal Hypoplasia | 2 | 2014 | 2 | 0.550 |
Why?
|
| Skin Diseases | 2 | 2014 | 32 | 0.540 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 73 | 0.530 |
Why?
|
| Monophenol Monooxygenase | 2 | 2013 | 11 | 0.530 |
Why?
|
| Iris Diseases | 1 | 2014 | 3 | 0.500 |
Why?
|
| Retinal Diseases | 1 | 2014 | 17 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2016 | 176 | 0.490 |
Why?
|
| Strabismus | 1 | 2014 | 17 | 0.490 |
Why?
|
| Hydrogen Sulfide | 4 | 2016 | 38 | 0.490 |
Why?
|
| Transcriptional Activation | 2 | 2011 | 164 | 0.480 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2013 | 17 | 0.480 |
Why?
|
| Vision Disorders | 1 | 2014 | 59 | 0.470 |
Why?
|
| Heterozygote | 4 | 2015 | 91 | 0.460 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 781 | 0.440 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 102 | 0.440 |
Why?
|
| Polymorphism, Genetic | 4 | 2015 | 165 | 0.430 |
Why?
|
| Amino Acid Sequence | 9 | 2022 | 1124 | 0.420 |
Why?
|
| Mixed Function Oxygenases | 5 | 2012 | 29 | 0.420 |
Why?
|
| Papillomavirus Infections | 1 | 2016 | 316 | 0.410 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2011 | 13 | 0.410 |
Why?
|
| Base Sequence | 5 | 2018 | 932 | 0.410 |
Why?
|
| Genetic Testing | 4 | 2011 | 71 | 0.400 |
Why?
|
| Cell Adhesion Molecules | 1 | 2011 | 70 | 0.400 |
Why?
|
| Hemoglobin, Sickle | 1 | 2010 | 13 | 0.390 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2010 | 5 | 0.390 |
Why?
|
| Humans | 32 | 2023 | 34853 | 0.380 |
Why?
|
| Transcription, Genetic | 2 | 2010 | 550 | 0.380 |
Why?
|
| Erythrocytes | 1 | 2010 | 107 | 0.370 |
Why?
|
| Proteins | 1 | 2012 | 352 | 0.360 |
Why?
|
| Child | 7 | 2023 | 2875 | 0.350 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 605 | 0.350 |
Why?
|
| Ectodermal Dysplasia | 3 | 2021 | 5 | 0.340 |
Why?
|
| Escherichia coli | 3 | 2010 | 436 | 0.330 |
Why?
|
| Molecular Sequence Data | 7 | 2016 | 1490 | 0.330 |
Why?
|
| Poly A | 1 | 2008 | 33 | 0.320 |
Why?
|
| DNA, Complementary | 2 | 2008 | 175 | 0.310 |
Why?
|
| Folic Acid | 2 | 2011 | 46 | 0.310 |
Why?
|
| Hemorrhage | 2 | 2019 | 46 | 0.300 |
Why?
|
| Exons | 2 | 2018 | 80 | 0.290 |
Why?
|
| Fibroblasts | 2 | 2021 | 252 | 0.270 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 968 | 0.260 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 600 | 0.260 |
Why?
|
| Homozygote | 5 | 2015 | 75 | 0.260 |
Why?
|
| Genotype | 7 | 2016 | 641 | 0.260 |
Why?
|
| Sequence Alignment | 5 | 2016 | 257 | 0.260 |
Why?
|
| Tyrosine | 3 | 2014 | 109 | 0.250 |
Why?
|
| Animals | 13 | 2022 | 14307 | 0.250 |
Why?
|
| Female | 17 | 2019 | 19873 | 0.250 |
Why?
|
| Male | 14 | 2016 | 18870 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 430 | 0.220 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2002 | 3 | 0.220 |
Why?
|
| Infant, Newborn | 5 | 2011 | 871 | 0.220 |
Why?
|
| Erythrocyte Volume | 1 | 2002 | 4 | 0.220 |
Why?
|
| Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2002 | 2 | 0.210 |
Why?
|
| Neural Tube Defects | 1 | 2002 | 3 | 0.210 |
Why?
|
| Pharmacogenetics | 3 | 2015 | 45 | 0.210 |
Why?
|
| Cloning, Molecular | 4 | 2008 | 310 | 0.210 |
Why?
|
| Codon, Nonsense | 2 | 2011 | 18 | 0.200 |
Why?
|
| Incidence | 1 | 2023 | 882 | 0.190 |
Why?
|
| Computational Biology | 1 | 2022 | 275 | 0.190 |
Why?
|
| Membrane Transport Proteins | 2 | 2014 | 88 | 0.190 |
Why?
|
| Hemeproteins | 2 | 2010 | 13 | 0.180 |
Why?
|
| Aged | 7 | 2016 | 6448 | 0.180 |
Why?
|
| Child, Preschool | 5 | 2013 | 1318 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2014 | 184 | 0.180 |
Why?
|
| Phylogeny | 2 | 2022 | 612 | 0.180 |
Why?
|
| Wetlands | 1 | 2018 | 15 | 0.170 |
Why?
|
| Heme | 4 | 2009 | 69 | 0.170 |
Why?
|
| Conserved Sequence | 1 | 2018 | 106 | 0.170 |
Why?
|
| Adult | 10 | 2019 | 11034 | 0.160 |
Why?
|
| Aspergillus | 1 | 2018 | 9 | 0.160 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 82 | 0.160 |
Why?
|
| Antibodies, Fungal | 1 | 2018 | 23 | 0.160 |
Why?
|
| Algorithms | 3 | 2016 | 435 | 0.160 |
Why?
|
| Antigens, Fungal | 1 | 2018 | 32 | 0.160 |
Why?
|
| Immunoglobulin E | 1 | 2018 | 54 | 0.160 |
Why?
|
| Mutation, Missense | 2 | 2015 | 80 | 0.160 |
Why?
|
| Allergens | 1 | 2018 | 58 | 0.160 |
Why?
|
| Mollusca | 2 | 2008 | 13 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 455 | 0.150 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 286 | 0.150 |
Why?
|
| Middle Aged | 8 | 2016 | 9642 | 0.140 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2016 | 26 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2016 | 1961 | 0.140 |
Why?
|
| Blotting, Northern | 2 | 2008 | 139 | 0.140 |
Why?
|
| Visual Acuity | 2 | 2014 | 98 | 0.140 |
Why?
|
| United States | 2 | 2023 | 3894 | 0.130 |
Why?
|
| Thrombosis | 1 | 2016 | 61 | 0.130 |
Why?
|
| Papillomaviridae | 1 | 2016 | 125 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 298 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2018 | 834 | 0.130 |
Why?
|
| Eye Color | 1 | 2014 | 3 | 0.130 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 105 | 0.130 |
Why?
|
| Adolescent | 5 | 2014 | 5035 | 0.120 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 89 | 0.120 |
Why?
|
| Pharmaceutical Preparations | 1 | 2015 | 74 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 484 | 0.120 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2012 | 28 | 0.110 |
Why?
|
| Gene Expression | 1 | 2016 | 639 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 105 | 0.110 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 126 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 185 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 638 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2012 | 984 | 0.110 |
Why?
|
| Cathepsin B | 1 | 2012 | 29 | 0.110 |
Why?
|
| Nuclear Proteins | 2 | 2010 | 287 | 0.100 |
Why?
|
| Kinetics | 4 | 2006 | 650 | 0.100 |
Why?
|
| Malabsorption Syndromes | 1 | 2011 | 3 | 0.100 |
Why?
|
| Reticulocyte Count | 1 | 2010 | 3 | 0.100 |
Why?
|
| Osteogenesis | 1 | 2010 | 31 | 0.100 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 31 | 0.100 |
Why?
|
| Neonatal Screening | 1 | 2010 | 26 | 0.100 |
Why?
|
| Protein Multimerization | 1 | 2011 | 97 | 0.100 |
Why?
|
| Immune System | 1 | 2010 | 40 | 0.100 |
Why?
|
| DNA | 2 | 2010 | 549 | 0.100 |
Why?
|
| Muscle Development | 1 | 2010 | 44 | 0.100 |
Why?
|
| Protein Engineering | 1 | 2010 | 40 | 0.090 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2015 | 13 | 0.090 |
Why?
|
| Amino Acid Substitution | 3 | 2009 | 122 | 0.090 |
Why?
|
| Metagenomics | 1 | 2009 | 32 | 0.090 |
Why?
|
| Ferric Compounds | 2 | 2006 | 49 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 431 | 0.080 |
Why?
|
| Protein Binding | 3 | 2009 | 913 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2010 | 145 | 0.080 |
Why?
|
| Prognosis | 1 | 2010 | 707 | 0.080 |
Why?
|
| Fovea Centralis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Alleles | 2 | 2015 | 284 | 0.080 |
Why?
|
| Ligands | 2 | 2005 | 317 | 0.080 |
Why?
|
| Gene Frequency | 3 | 2015 | 155 | 0.080 |
Why?
|
| Aged, 80 and over | 4 | 2016 | 2333 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1442 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 528 | 0.080 |
Why?
|
| Binding Sites | 2 | 2010 | 597 | 0.070 |
Why?
|
| HIV-1 | 1 | 2012 | 678 | 0.070 |
Why?
|
| Sequence Deletion | 1 | 2006 | 87 | 0.070 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2005 | 6 | 0.070 |
Why?
|
| Hemostatics | 1 | 2005 | 8 | 0.070 |
Why?
|
| Neurons | 1 | 2012 | 1130 | 0.060 |
Why?
|
| Apoptosis | 1 | 2012 | 1317 | 0.060 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2004 | 94 | 0.060 |
Why?
|
| Genetic Vectors | 1 | 2004 | 154 | 0.060 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2004 | 168 | 0.060 |
Why?
|
| Young Adult | 1 | 2014 | 4012 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2004 | 129 | 0.060 |
Why?
|
| Codon | 1 | 2003 | 38 | 0.060 |
Why?
|
| Temperature | 1 | 2004 | 275 | 0.060 |
Why?
|
| Pedigree | 2 | 2014 | 64 | 0.060 |
Why?
|
| Prevalence | 3 | 2015 | 1425 | 0.060 |
Why?
|
| Phenotype | 2 | 2019 | 650 | 0.060 |
Why?
|
| Infant | 1 | 2006 | 1014 | 0.050 |
Why?
|
| Prenatal Diagnosis | 1 | 2002 | 10 | 0.050 |
Why?
|
| Alanine | 1 | 2002 | 28 | 0.050 |
Why?
|
| Valine | 1 | 2002 | 31 | 0.050 |
Why?
|
| Risk | 1 | 2002 | 256 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2016 | 1422 | 0.050 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 102 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2018 | 79 | 0.040 |
Why?
|
| Ferrous Compounds | 2 | 2009 | 20 | 0.040 |
Why?
|
| Pregnancy | 1 | 2002 | 1503 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 255 | 0.040 |
Why?
|
| Spectrum Analysis, Raman | 2 | 2009 | 84 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 445 | 0.040 |
Why?
|
| Drug Dosage Calculations | 1 | 2016 | 2 | 0.040 |
Why?
|
| Half-Life | 1 | 2016 | 52 | 0.040 |
Why?
|
| Caribbean Region | 1 | 2016 | 63 | 0.030 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2015 | 17 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 628 | 0.030 |
Why?
|
| Demography | 1 | 2016 | 167 | 0.030 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 2 | 2005 | 67 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2015 | 25 | 0.030 |
Why?
|
| Crystallography | 1 | 2014 | 6 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2015 | 83 | 0.030 |
Why?
|
| Turkey | 1 | 2014 | 19 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2014 | 85 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1056 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 195 | 0.030 |
Why?
|
| Hydrogen Peroxide | 2 | 2006 | 181 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2006 | 342 | 0.030 |
Why?
|
| Cystatin B | 1 | 2012 | 8 | 0.030 |
Why?
|
| Basal Ganglia | 1 | 2012 | 17 | 0.030 |
Why?
|
| Cystatin C | 1 | 2012 | 21 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2014 | 347 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2012 | 35 | 0.030 |
Why?
|
| Lysosomes | 1 | 2012 | 80 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2012 | 429 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2012 | 160 | 0.030 |
Why?
|
| Facies | 1 | 2010 | 3 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2010 | 5 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2010 | 9 | 0.020 |
Why?
|
| Syndrome | 1 | 2010 | 72 | 0.020 |
Why?
|
| Chromosome Mapping | 1 | 2010 | 159 | 0.020 |
Why?
|
| Monocytes | 1 | 2012 | 258 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 103 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 32 | 0.020 |
Why?
|
| Electron Transport | 1 | 2009 | 38 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 55 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2009 | 162 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2009 | 67 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 350 | 0.020 |
Why?
|
| Cognition | 1 | 2012 | 373 | 0.020 |
Why?
|
| Hippocampus | 1 | 2012 | 546 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2012 | 1353 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 188 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2009 | 376 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2007 | 7 | 0.020 |
Why?
|
| Body Weights and Measures | 1 | 2007 | 23 | 0.020 |
Why?
|
| Tomography, Optical Coherence | 1 | 2007 | 42 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 897 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 751 | 0.020 |
Why?
|
| Cyanides | 1 | 2005 | 10 | 0.020 |
Why?
|
| Carbon Monoxide | 1 | 2005 | 30 | 0.020 |
Why?
|
| Hydrogen Bonding | 1 | 2006 | 119 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 2128 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2005 | 5 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2005 | 383 | 0.020 |
Why?
|
| Aminolevulinic Acid | 1 | 2004 | 8 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2004 | 201 | 0.010 |
Why?
|
| Iron | 1 | 2004 | 204 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2004 | 485 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 2561 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 1349 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 5668 | 0.010 |
Why?
|